XNAS
CHRN
Market cap56mUSD
Jun 18, Last price
23.33USD
1D
13.20%
1Q
121.35%
Jan 2017
-97.39%
IPO
-99.37%
Name
Ekso Bionics Holdings Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Ekso Bionics Holdings, Inc. is a global innovator in exoskeleton technology, specializing in the creation, production, sale, and leasing of these advanced devices across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. The company's operations are divided into two distinct segments: EksoHealth and EksoWorks. The EksoHealth division concentrates on engineering, manufacturing, and marketing exoskeletons designed for medical applications. Conversely, the EksoWorks segment develops and commercializes exoskeleton solutions intended for able-bodied individuals, empowering them to perform demanding, repetitive physical tasks for extended durations. Its product portfolio includes EksoNR, a sophisticated wearable bionic suit and rehabilitation tool. This device supports physical therapists and physicians in treating patients recovering from conditions such as acquired brain injury, stroke, and spinal cord injury. Additionally, the EksoUE is an assistive wearable device for the upper extremities, designed to lessen the gravitational load on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. also maintains a licensing agreement with Lockheed Martin Corporation. Founded in 2005, the company maintains its corporate headquarters in Richmond, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||